Related Experiment Video
Updated: Aug 26, 2025

Highlighting and Reducing the Impact of Negative Aging Stereotypes During Older Adults' Cognitive Testing
Published on: January 24, 2020
How "age-friendly" are deprescribing interventions? A scoping review of deprescribing trials
Jinjiao Wang1, Jenny Y Shen2, Yeates Conwell3
1Elaine Hubbard Center for Nursing Research on Aging, School of Nursing, University of Rochester, Rochester, New York, USA.
Objective:
To assess how age-friendly deprescribing trials are regarding intervention design and outcome assessment. Reduced use of potentially inappropriate medications (PIMs) can be addressed by deprescribing-a systematic process of discontinuing and/or reducing the use of PIMs. The 4Ms-"Medication", "Mentation", "Mobility", and "What Matters Most" to the person-can be used to guide assessment of age-friendliness of deprescribing trials.
Data Source:
Published literature.
Study Design:
Scoping review.
Data Extraction Methods:
The literature was identified using keywords related to deprescribing and polypharmacy in PubMed, EMBASE, Web of Science, ProQuest, CINAHL, and Cochrane and snowballing. Study characteristics were extracted and evaluated for consideration of 4Ms.
Principal Findings:
Thirty-seven of the 564 trials identified met the review eligibility criteria. Intervention design: "Medication" was considered in the intervention design of all trials; "Mentation" was considered in eight trials; "Mobility" (n = 2) and "What Matters Most" (n = 6) were less often considered in the design of intervention. Most trials targeted providers without specifying how matters important to older adults and their families were aligned with deprescribing decisions.
Outcome Assessment:
"Medication" was the most commonly assessed outcome (n = 33), followed by "Mobility" (n = 13) and "Mentation" (n = 10) outcomes, with no study examining "What Matters Most" outcomes.
Conclusions:
"Mentation" and "Mobility", and "What Matters Most" have been considered to varying degrees in deprescribing trials, limiting the potential of deprescribing evidence to contribute to improved clinical practice in building an age-friendly health care system.
Related Concept Videos
Antidepressant Drugs: Overview
Antidepressant Drugs: MAOIs and Other Agents
Drug Therapy
Antianxiety Medications
Alzheimer's Disease: Treatment
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Drug Abuse and Addiction: Pharmacological Phenomena

